James Kochenderfer

University Name

United States

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (20)

Collaborators (5)

Hao-Wei Wang

Head, FLOW CYTOMETRY LABORATORY

National Cancer Institute

UNITED STATES

David Siegel

Chief, Myeloma Division

UNITED STATES

Amer Beitinjaneh

Associate Professor

University of Miami Hospital

UNITED STATES

Emmie de Wit

NIAID Rocky Mountain Laboratories

UNITED STATES

Elodie Ghedin

National Institute of Allergy and Infectious Diseases

UNITED STATES

James Kochenderfer

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (5)

Hao-Wei Wang

David Siegel

Amer Beitinjaneh

Emmie de Wit

Elodie Ghedin

How do I reach out?

Meet Kite AI

James Kochenderfer

Research Interests

Explore related searches

Contact this professor

Articles (20)

Chimeric antigen receptor T cell therapy for autoimmune disease

Current understanding and management of CAR T cell-associated toxicities

FDA approval of the first cellular therapy for a solid (non-hematologic) cancer

Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30<sup>+</sup> lymphomas: results of a phase 1 trial

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Crystal Structure of a Chimeric Antigen Receptor (CAR) scFv Domain Rearrangement Forming a VL-VL Dimer

Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*

Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient with B-Cell Depletion

Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

CAR T cell therapies for patients with multiple myeloma

Design and assessment of novel Anti-CD30 chimeric antigen receptors with human antigen-recognition domains

Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains (Nature Communications, (2020), 11, 1, (283), 10.1038/s41467-019-14119-9)

Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (Nature Medicine, (2020), 26, 2, (270-280), 10.1038/s41591-019-0737-3)

Collaborators (5)

Hao-Wei Wang

David Siegel

Amer Beitinjaneh

Emmie de Wit

Elodie Ghedin

How do I reach out?

Meet Kite AI